AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution.

ABSTRACT: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest rate of recurrence¹. The predominant standard of care for advanced TNBC is systemic chemotherapy with or without immunotherapy; however, responses are typically short lived^1,2. Thus, there is an urgent need to develop more effective treatments. Components of the PI3K pathway represent plausible therapeutic targets; more than 70% of TNBCs have alterations in PIK3CA, AKT1 or PTEN^3-6. However, in contrast to hormone-receptor-positive tumours, it is still unclear whether or how triple-negative disease will respond to PI3K pathway inhibitors⁷. Here we describe a promising AKT-inhibitor-based therapeutic combination for TNBC. Specifically, we show that

SUBMITTER: Schade AE 

PROVIDER: S-EPMC11578877 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature